Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.87 |
| ▸ | PKM | P14618 | 3/20 | 0.69 |
| ▸ | F13A1 | P00488 | 1/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | TGM1 | P22735 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GCK | P35557 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | BCR | P11274 | 1/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335588 | 0.88 | L3MBTL1 (0.91) | KDM4EL3MBTL1PKMF13A1TGM2 | |
| SCHEMBL2155799 | 0.85 | KDM4E (0.74) | KDM4EL3MBTL1PKMF13A1TGM2 | |
| SCHEMBL12965423 | 0.81 | KDM4E (0.68) | KDM4EL3MBTL1F13A1TGM2TGM1 | |
| SCHEMBL6348135 | 0.81 | KDM4E (0.66) | KDM4EL3MBTL1PKMF13A1TGM2 | |
| SCHEMBL4754464 | 0.80 | KDM4E (0.67) | KDM4EL3MBTL1PKMF13A1TGM2 | |
| SCHEMBL12828294 | 0.80 | KDM4E (0.65) | KDM4EL3MBTL1PKMF13A1TGM2 | |
| SCHEMBL5357244 | 0.80 | KDM4E (0.66) | KDM4EL3MBTL1PKMALDH1A1KMT2A | |
| SCHEMBL1471121 | 0.79 | KDM4E (0.64) | KDM4EL3MBTL1PKMF13A1TGM2 | |
| SCHEMBL941442 | 0.79 | GAA (0.68) | KDM4EL3MBTL1PKMF13A1TGM2 | |
| SCHEMBL7462550 | 0.79 | KDM4E (0.65) | KDM4EL3MBTL1PKMF13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | claimed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | GLP1R, GPR119, INSR | KDM4E 2658/4885L3MBTL1 3230/4885PKM 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.